Spyre Therapeutics, Inc.
- Stock
- Ticker SYRE
- ISIN US00773J2024
- Nasdaq
Performance, volatility and drawdowns of Spyre Therapeutics, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.
Performance
$10,000 grew to $6,348. Global equities (VT): $29,042.
Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.
Declines from the peak
Lowest point −99.0% in 06/2023, measured from the peak in 06/2020. The old peak has not been reached again yet.
Financial statements
Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures
| Quarter end | 12/2024 | 03/2025 | 06/2025 | 09/2025 | 12/2025 | 03/2026 | 06/2026 | 09/2026 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0.0 | – | – | – | – | – | – | – |
| Operating income | -61 | -54 | -42 | -57 | -57 | -46 | -42 | -106 |
| EBITDA | -61 | – | – | – | – | – | – | – |
| Net income | -56 | -45 | -37 | -11 | -63 | -69 | -36 | -96 |
| Earnings per share | – | – | – | -0.15 | – | -0.74 | -0.35 | -0.95 |
| Balance sheet | ||||||||
| Total assets | 608 | 570 | 539 | 505 | 778 | 764 | 1,173 | 1,100 |
| Liabilities | 91 | 87 | 83 | 50 | 63 | 93 | 72 | 48 |
| Equity | 518 | 483 | 456 | 455 | 715 | 671 | 1,101 | 1,052 |
| Cash | 89 | 48 | 82 | 65 | 86 | 97 | 162 | 83 |
| Cash flow | ||||||||
| Operating cash flow | -37 | -41 | -47 | -37 | -45 | -57 | -70 | -77 |
| Free cash flow | -37 | -41 | -47 | -37 | -45 | -57 | -70 | -77 |
Value it:DCF calculatorMultiples calculator
Annual returns
Best year 2023 at +91.3%, weakest 2022 at −90.5%. 7 of 9 full years were positive. * partial year.
Quarterly reports
Filing date with the SEC and earnings per share of the quarter
| Day | Earnings per share |
|---|---|
| 3 Nov 2026 | −$0.95 |
| 4 Aug 2026 | −$0.35 |
| 5 May 2026 | −$0.74 |
| 19 Feb 2026 | – |
| 4 Nov 2025 | −$0.15 |
| 5 Aug 2025 | – |
| 8 May 2025 | – |
| 27 Feb 2025 | – |
| 7 Nov 2024 | $1.06 |
| 7 Aug 2024 | $0.59 |
| 9 May 2024 | $0.72 |
| 29 Feb 2024 | −$0.89 |
Key metrics
Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.
Valuation
- Market cap
- €8.0bn
- Market cap in trading currency
- $8.88bn
- Enterprise value
- $7.80bn
- P/E
- –
- P/S
- –
- P/B
- 8.44
- EV/Sales
- –
- EV/EBITDA
- –
- Earnings yield
- –
- FCF yield
- -2.8%
Results (last four quarters)
- Revenue
- –
- Gross profit
- –
- EBITDA
- –
- Net income
- −$264m
- Earnings per share
- –
- Revenue per share
- –
- Revenue growth
- –
- Earnings growth
- –
Profitability
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity
- -35.0%
- Return on assets
- -24.0%
Balance sheet and cash flow
- Cash
- $1.07bn
- Cash per share
- $11.29
- Financial debt
- –
- Debt/equity %
- –
- Current ratio
- 27.40
- Book value per share
- $11.07
- Operating cash flow
- −$249m
- Free cash flow
- −$249m
Dividend
- Dividend yield
- 0.00%
- Dividend (12 months)
- $0.00
- Yield (12 months)
- 0.00%
- Payout ratio
- –
- Ex-dividend date
- –
Shares and trading
- Shares outstanding
- 95.0m
- Volume
- 800,714
- Avg. volume 3 months
- 1.27m
- Relative volume
- 0.6
Price and technicals
- Price
- $93.47
- 1 day
- −4.3%
- 52-week high
- $109.00
- 52-week low
- $23.47
- Distance to 52-week high
- −14.2%
- Distance to 52-week low
- +298.3%
- Distance to 50-day line
- +1.3%
- Distance to 200-day line
- +19.4%
- RSI (14)
- 46
- Volatility 1M
- 66.0%
Performance
- 1 week
- −10.1%
- 1 month
- +1.2%
- 3 months
- −12.4%
- 6 months
- +26.2%
- YTD
- +185.3%
- 1 year
- +284.7%
Dates
- Fiscal year end
- 31 Dec 2025
- Most recent quarter
- 30 Sep 2026
Frequently asked questions
How has SYRE performed since 11/2016?
$10,000 grew to $6,348 by 20 Nov 2026, which is −4.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.
How volatile is SYRE?
Volatility was 111.9% per year, measured on monthly returns. The largest decline from a peak was −99.0%, with the low in 06/2023.
How does SYRE compare with a broad equity ETF?
Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, SYRE returned −4.4% at 111.9%. The correlation of monthly returns was 0.30; 1 would mean they moved in lockstep.
Which currency are the figures in?
In US dollars, the currency of the US listing.